HemoGenyx Pharmaceuticals

Receive alerts
Market Cap:
£29.31 m
6.64 GBX
52 weeks high
52 weeks low

In brief

HemoGenyx Pharmaceuticals PLC. is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned US operating subsidiary, HemoGenyx LLC, located in Brooklyn, New York at its state- of- the- art research facility ("HemoGenyx").

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risk of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is used only as a last resort and its use is restricted. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases, such as leukemia and lymphoma, as well as severe autoimmune diseases, such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

HemoGenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.


"With multiple collaboration agreements and investment from industry we view the company as undervalued," says Northland

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Are small-cap biotech stocks good investments now?

We look at the sector's success stories and assess what we can expect in the coming months

on 15/8/20